In a meta-analysis conducted by Buchynskyi et al., the administration of IFN-α during COVID-19 did not demonstrate consistent positive clinical outcomes, such as shortening the length of hospital stay or the viral elimination period (81). Here, IFNA1 is linked to COVID-19.